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Abstract
Background: Rheumatic heart disease (RHD) is an autoimmune disease where cross reactive CD4+ T cells are
involved in the pathogenesis of valvular damage. Human Leukocyte Antigen-G (HLA-G), an immunosuppressive
molecule playing a crucial role in the inhibition of T cell response is associated with the pathogenesis of various
autoimmune and inflammatory diseases. Genetic polymorphisms within the 3′untranslated region (UTR) of HLA-G
influences its expression and thus disease pathogenesis. Hence, the present study aims to unravel the association of
14 bp Ins/Del (rs66554220) and +3142 C/G (rs1063320) polymorphisms in 3′ UTR of HLA-G with RHD.
Methods: This familial study consists of 99 RHD families (99 RHD patients, 140 parents and 126 healthy siblings).
The 14 bp Ins/Del and +3142 C/G polymorphisms were evaluated by PCR using sequence specific primers and its
transmission disequilibrium (TD) was tested by TD test in 70 trio families.
Results: The frequency of +3142 C/C genotype was high in patients with combined valvular lesions (CVL) (OR = 5.88;
pc = 0.012) and pooled RHD patients (P: OR = 2.76; p = 0.043; pc = 0.076) when compared to healthy siblings. Under the
additive (OR = 5.50; pc = 0.026) and recessive genetic model (OR = 5.88; pc = 0.012), the +3142 C/C genotype was
significantly associated with CVL in patients.
Conclusion: The results suggest that the +3142 C/C genotype may be associated with minor risk for the development
of RHD and is more likely to influence the severity of the disease.
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Background
RHD is an autoimmune disease occurring as a result of
group A β-hemolytic Streptococcus (GAS) infection
followed by rheumatic fever (RF) [1]. Molecular mimicry
between streptococcal M protein and human cardiac
proteins leads to the development of RHD in a suscep-
tible host [2]. RHD causes major cardiac illness, subse-
quently leading to high morbidity and mortality among
children in developing countries and also in certain indi-
genous populations within developed countries. Glo-
bally, over 15 million cases of RHD have been reported
and its prevalence in India ranges from 2–2.5 million [3,
4]. It is an inflammatory condition resulting in chronic
valvular damage specifically mediated by cellular im-
mune response. The aberrant immune response against
host cardiac proteins may account for the progressive
valvular damage [5–9].
HLA-G is a non-classical class-I HLA molecule associ-
ated with anti-inflammatory and immuno-modulatory
properties [10, 11] which interacts with inhibitory recep-
tors (ILT2/ILT4/KIR2DL4) present on various immune
cells. It inhibits proliferation of B cells, T cells and natural
killer cells; and also induces regulatory T cells (T-reg)
[12–15]. The polymorphic 3’UTR of HLA-G plays a vital
role in the regulation of HLA-G expression. The 14bp
Ins/Del polymorphism regulates HLA-G expression by in-
fluencing the splicing pattern and stability of mRNA.
Whereas, the +3142 C/G polymorphism enhances the af-
finity for micro RNAs and downregulate the expression of
HLA-G [16–19]. Thus, both the polymorphisms influence
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HLA-G expression and are associated with various auto-
immune and inflammatory diseases [20, 21]. Several stud-
ies have demonstrated the genetic predisposition to RHD,
especially those genes which are involved in immune re-
sponse [22]. However, the role of HLA-G in the pathogen-
esis of RHD has not been reported yet. Hence, the aim of
this study is to evaluate the possible role of HLA-G gene
polymorphisms with particular importance to 14bp Ins/
Del (rs66554220) and +3142C/G (rs1063320) variants




This family based retrospective study consisted of 365
individuals (99 RHD patients, 140 parents and 126
healthy siblings, which includes 70 trios), recruited from
the Institute of Child Health and Research Centre,
Government Rajaji Hospital, Madurai, India. The study
was approved by ethics committees of the participating
institutions and was carried out in accordance with the
declaration of Helsinki. Patients with ARF were diag-
nosed based on modified Jones criteria. They clinically
present with migrating polyarthritis, carditis and chorea.
Based on echocardiographic data, the patients were
classified into three subgroups: (i) rheumatic fever (RF) -
patients without residual valvular disease; (ii) mitral
valvular lesions (MVL) - patients with mitral valvular
lesions only; (iii) combined valvular lesions (CVL) -
patients with multiple valvular lesions along with MVL.
Further, the severity of valve damage was assessed by
investigations like echo cardiogram showing Mitral/
Aortic/Tricuspid valve morphology, color flow doppler
MR/AR/TR jet, vena contracta width, effective regur-
gitant orifice area, left atrium (LA) and left ventricle
(LV) size, pulmonary arterial pressure, pulmonary vein
flow and hepatic vein flow. In addition, regurgitaion
is clinically diagnosed by prominent pulsations of the
jugular veins, systolic pulsations of the liver and a
blowing holosystolic murmur at the lower left sternal
border which increases in intensity during inspiration
and expiration for TR and MR respectively. Currently,
all the patients in the study group are in quiescent phase,
under penicillin (tablet) prophylaxis against rheumatic
fever recurrence. Patients with carditis were treated with
steroids (oral prednisone 2mg/Kg) initially and subse-
quently treated with aspirin tablets. Antifailure drugs like
frusemide, digoxin and enalapril were given appropriately
to the patients with congestive cardiac failure. None of
the patients underwent surgery for valvular heart disease
in this study group. Siblings, free from autoimmune and
cardiac diseases were considered as controls. Like the pa-
tients, the siblings are under follow-up at regular inter-
vals. None of the siblings developed any symptoms of
ARF like, polyarthritis, carditis, chorea, erythema margin-
atum and subcutaneous nodules during the follow-up
period. The siblings are advised to be under regular
follow-up. Blood samples (2.5 ml) were collected from all
the participating individuals with their consent. For chil-
dren (<18 years), the consent was duly signed by their
parents.
Genotyping of HLA-G gene polymorphisms
Genomic DNA was extracted from the blood samples by
salting out method [23]. HLA-G 14 bp Ins/Del and
+3142 C/G polymorphisms were examined by direct
PCR DNA amplification method [24]. Further, validation
of 14 bp Ins/Del polymorphism was also performed by
PCR-SSP [25].
Statistical analysis
Hardy-Weinberg equilibrium (HWE), TDT, linkage
disequilibrium (LD) and haplotype analysis was per-
formed using Haploview v4.2 [26]. The HLA-G allelic
and genotypic frequencies of patients and siblings
were compared using the Fisher’s exact test or Pearson’s
χ2 test with Yates correction using Epi Info v7. The odds
ratio (OR) with 95% confidence interval (CI) was
calculated and the p <0.05 was considered statistically
significant.
Results
Characteristics of the study population
This familial study included 99 RHD patients (52 males,
47 females, mean age 11.2 ± 2.5 years), 126 healthy siblings
(75 males and 51 females, mean age 12.2 ± 4.3 years)
and 140 parents (70 mothers and 70 fathers). The
demographic and clinical characteristics of the study
subjects is represented in Table 1. In this study
group, migrating polyarthritis was present in 80 pa-
tients and carditis was seen in 56 patients. In
addition, chorea was present in 7 patients while ery-
thema marginatum and subcutaneous nodules were
not seen even in a single patient. Out of 99 patients,
10 (10.1%) patients had RF, 67 (67.7%) had MVL and
22 (22.2%) had CVL.
Transmission disequilibrium test (TDT)
In the present study, 70 trio families were included
for TDT analysis (Table 2). No Mendelian error was
observed and the families were in HWE expectations.
In single marker analysis, Del allele (32 T vs 28 UT;
p = 0.606) and G allele (27 T vs 23 UT; p = 0.572)
were overtransmitted, however no statistical signifi-
cance was observed. Likewise, the haplotype analysis
also showed no significance among Ins/G (28 T vs. 31
UT; p = 0.697), Del/G (28.5 T vs. 20.5 UT; p = 0.255)
and Del/C haplotypes (23.5 T vs. 27.5 UT; p = 0.578).
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Linkage disequilibrium analysis
Pairwise linkage disequilibrium analysis was carried
out for the two polymorphic sites of the HLA-G gene
in the study population. The haplotype analysis pre-
dicted a single block of high LD in healthy siblings
(D’ = 1, LOD = 10.57 and r2 = 0.38), RHD patients (D’ = 1,
LOD = 10.56 and r2 = 0.32) and Trios (D’ = 0.966;
LOD = 17.82; r2 = 0.285) between HLA-G 14 bp Ins/
Del and +3142 C/G polymorphism (Additional file 1:
Figure S1).
Genotype and Allele distribution in RHD patients and
healthy siblings
The genotype and allele frequencies of 14bp Ins/Del and
+3142 C/G polymorphisms for pooled (P) RHD patients
and healthy siblings were shown in Table 3. The data
was further stratified based on gender (male (M) and fe-
male (F)). There were no significant differences observed
for the genotype and allele frequencies of these two
polymorphisms between RHD patients and healthy
siblings.
In 14 bp Ins/Del polymorphism, an increased frequen-
cies of Ins/Ins genotype (OR = 2.86; pc = 0.241) and Ins
allele (OR = 1.14; pc = 0.766) were observed in female
RHD patients. Moderately increased frequencies were
noticed in Del/Del genotype (P: OR = 1.37; pc = 0.312)
and Del allele (P: OR = 1.28; pc = 0.236) among pooled
RHD patients. The subgroup analysis showed increased
frequencies of Del/Del genotype in CVL (OR = 1.73;
pc = 0.363) and MVL patients (OR = 1.39; pc = 0.383)
(Table 4). In addition, increased frequency of Del al-
lele was observed in MVL (OR = 1.37; pc = 0.184) and
CVL patients (OR = 1.25; 0.607).
The +3142 C/C genotype frequency was relatively
high in pooled RHD patients (P: OR = 2.76; p = 0.043;
pc = 0.076). Significantly increased frequency of +3142
C/C genotype was found in CVL patients (OR = 5.88;
pc = 0.012) when compared to healthy siblings (Table 4).
In the genetic model analysis, the additive (OR = 5.50;
pc = 0.026) and recessive pattern (OR = 5.88; pc = 0.012) of
+3142 C/C genotype was inherited significantly among
CVL patients (Table 5) when compared to healthy sib-
lings. The +3142 C/C genotype frequency was higher in
male RHD patients (M: OR = 3.68; pc = 0.112) when com-
pared to female RHD patients (F: OR = 1.94; pc = 0.604).
The three possible haplotypes observed in the present
study were Ins/G, Del/G and Del/C. The frequency dis-
tribution of these haplotypes among the study groups
did not show statistical significance (Table 3). However,
increased frequency of Del/C haplotype was observed in
pooled RHD (P: OR = 1.31; pc = 0.228) and CVL patients
(OR = 1.78; pc = 0.130) (Table 4) while Ins/G haplotype
was found to be high among female RHD patients (F:
OR = 1.14; pc = 0.766).
Table 1 Demographic characteristics and clinical details of
patients and healthy siblings
Parameters Patients
N = 99 (%)
Healthy siblings
N = 126 (%)
Age, in years (mean ± SD) 11.2 ± 2.5 12.2 ± 4.3
Gender
Male 52 (52.5) 75 (59.5)
Female 47 (47.5) 51 (40.5)
Patient classification
Rheumatic Fever 10 (10.1)
Valvular Lesions
MVL 67 (67.7)
Mitral Regurgitation Mild 24 (35.8)
Moderate - Severe 35 (52.2)
MR with MS 3 (4.5)
Mild MR, Mild MS 1 (33.3)
Moderate MR, Mild MS 2 (66.7)
MR with chorea 5 (7.5)
Mild MR with chorea 4 (80.0)
Moderate MR with chorea 1 (20.0)
CVL 22 (22.2)
MR, AR 17 (77.3)
Mild MR, Mild AR 6 (35.3)
Moderate MR, Mild AR 6 (35.3)
Moderate MR, Mod AR 1 (5.9)
Severe MR, Mild AR 3 (17.6)
Severe MR, Mod AR 1 (5.9)
MR, TR 2 (9.1)
Severe MR, Mild TR 2 (100)
MR, MS, AR 3 (13.6)
Mild MR, Severe MS, Mild AR 1 (33.3)
Mod MR, Mod MS, Mild AR 2 (66.7)
SD Standard Deviation, MVL Mitral Valvular Lesions, MR Mitral Regurgitation,
MS Mitral Stenosis, CVL Combined Valvular Lesions, AR ortic Regurgitaion,
TR Triscuspid Regurgitation, Mod Moderate
Table 2 TDT of HLA-G polymorphisms in 70 trio families
T UT χ2 p value
14 bp Ins/Del
Del allele 32 28 0.267 0.6056
+3142 C/G
G allele 27 23 0.320 0.5716
Haplotypes
Ins/G 28 31 0.152 0.6969
Del/G 28.5 20.5 1.295 0.2552
Del/C 23.5 27.5 0.309 0.5782
TDT transmission disequilibrium test, T transmitted, UT untransmitted
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Discussion
RHD is an autoimmune disease characterised by persist-
ent inflammatory reaction towards valvular tissue. HLA-
G has an immunoregulatory function and could play a
vital role in the pathogenesis of immune-mediated dis-
eases, including RHD. To our knowledge, this is the first
study to investigate the association of HLA-G 14 bp Ins/
Del and +3142 C/G polymorphisms with the pathogen-
esis of RHD. Hence, we validate our findings with previ-
ous reports on various autoimmune diseases such as
systemic lupus erythematosus (SLE), rheumatoid arth-
ritis (RA), type 1 diabetes (T1D), idiopathic dilated
cardiomyopathy (IDC), and juvenile idiopathic arthritis
(JIA) [27–38].
In the present study, the TDT analysis showed that the
Del allele was overtransmitted in RHD patients. In
addition, the Del/Del genotype and Del allele were over-
represented in pooled RHD patients when compared to
healthy siblings. This is in agreement with the previous
studies carried out on autoimmune diseases such as
T1D, IDC and JIA [33–35]. Increased frequencies of Ins/
Ins genotype and Ins allele were observed in female
RHD patients, which differ from the previous finding of
increased frequency of Del allele among female JIA pa-
tients [35]. Increased frequencies of Ins allele and Ins/
Ins genotypes were documented in SLE patients [27, 28,
36, 37], however no association of HLA-G 14 bp Ins/Del
polymorphism was reported in SLE [31, 38] and RA pa-
tients [32, 35].
In this study, the TDT analysis revealed that the +3142
G allele was overtransmitted from parents to RHD pa-
tients. We could observe a borderline association of
+3142 C/C genotype with susceptibility to RHD. In
addition, the frequency of +3142 C/C genotype was sig-
nificantly high among CVL patients when compared to
healthy siblings. Thus the recessive and additive model





OR (95% CI) pc MVL 67
n (%)
OR (95% CI) pc CVL 22
n (%)
OR (95% CI) pc
14 bp Ins/Del
Genotypes
Ins/Ins 27 (21.4) 2 (20.0) 0.92 (0.18-4.57) 0.7680 9 (13.4) 0.57 (0.25-1.29) 0.2446 5 (22.7) 1.08 (0.36-3.19) 0.8854
Del/Del 36 (28.6) 2 (20.0) 0.62 (0.13-3.09) 0.8294 24 (35.8) 1.39 (0.74-2.62) 0.3829 9 (40.9) 1.73 (0.68-4.40) 0.3630
Ins/Del 63 (50.0) 6 (60.0) 1.5 (0.40-5.57) 0.7792 34 (50.8) 1.03 (0.57-1.86) 0.9581 8 (36.4) 0.57 (0.22-1.46) 0.3421
Alleles
Ins 117 (46.4) 10 (50.0) 1.15 (0.46-2.86) 0.9399 52 (38.8) 0.73 (0.48-1.12) 0.1837 18 (40.9) 0.80 (0.42-1.53) 0.6070
Del 135 (53.6) 10 (50.0) 0.87 (0.35-2.15) 0.9399 82 (61.2) 1.37 (0.89- 2.09) 0.1837 26 (59.1) 1.25 (0.65-2.40) 0.6070
+3142 C/G
Genotypes
C/C 6 (4.8) 0 0 0.9250 7 (10.5) 2.33 (0.75-7.25) 0.2306 5 (22.7) 5.88 (1.62-21.39) 0.0116 a
G/G 66 (52.4) 4 (40.0) 0.61 (0.16-2.25) 0.6705 34 (50.7) 0.94 (0.52-1.69) 0.9481 10 (45.5) 0.76 (0.30-1.89) 0.7124
C/G 54 (42.8) 6 (60.0) 2.0 (0.54-7.44) 0.4714 26 (38.8) 0.84 (0.46-1.55) 0.6962 7 (31.8) 0.62 (0.24-1.63) 0.4618
Alleles
C 66 (26.2) 6 (30.0) 1.21 (0.44-3.27) 0.9136 40 (29.9) 1.20 (0.75-1.90) 0.5174 17 (38.6) 1.78 (0.91-3.46) 0.1300
G 186 (73.8) 14 (70.0) 0.83 (0.30-2.24) 0.9136 94 (70.1) 0.83 (0.52-1.33) 0.5174 27 (61.4) 0.56 (0.29-1.10) 0.1300
Haplotypes
Ins/G 117 (46.4) 10 (50.0) 1.15 (0.46-2.86) 0.9399 52 (38.8) 0.73 (0.48-1.12) 0.1837 18 (40.9) 0.80 (0.42-1.53) 0.6070
Del/G 69 (27.4) 4 (20.0) 0.66 (0.21-2.05) 0.6491 42 (31.3) 1.21 (0.76-1.91) 0.4835 9 (20.5) 0.68 (0.31-1.49) 0.4372
Del/C 66 (26.2) 6 (30.0) 1.21 (0.44-3.27) 0.9136 40 (29.9) 1.19 (0.75-1.91) 0.5174 17 (38.6) 1.78 (0.91-3.46) 0.1300
RF- Rheumatic Fever, MVL-Mitral Valvular Lesions, CVL-Combined Valvular Lesions, CI-confidence interval, OR-odds ratio, pc-Yates corrected p value
a - χ2 = 6.3692, Fisher Exact P (Pf) = 0.0117
Bold - significant p value (<0.05)
Table 5 Analysis of Genotype as risk factor in CVL patients
Study models OR (95% CI) pc
CC + CG vs GGa
CC vs GGb
CC vs GG + CGc









CVL Combined Valvular Lesions, CI-confidence interval, OR odds ratio, pc-Yates
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analysis revealed that +3142 C/C genotype was signifi-
cantly associated with risk for CVL. Likewise, the +3142
C allele was associated with risk for clinical subtypes of
SLE patients in Japanese population [27]. In contrast,
the +3142 G/G genotype and G allele were associated
with susceptibility to SLE [28, 29] and RA [30] in Brazil-
ian populations. However, no association of +3142 C/G
polymorphism was observed in Brazilian and South
Indian RA patients [31, 32].
Our results did not reveal any significant difference in
the haplotype frequencies of Ins/G, Del/G and Del/C in
the study population. However, increased frequencies of
Del/C haplotype was observed in pooled RHD patients
and among the patient subgroups. Conversely a previous
study reported the association of Del/C haplotype with
protection to SLE [29] and RA [30]. Several studies re-
ported that Del/C haplotype is associated with high level
of HLA-G expression while Ins/G haplotype is associ-
ated with low level of HLA-G expression [39]. In
addition, there might be other polymorphic loci in the
3’UTR and promoter region with strong LD which could
regulate the HLA-G expression [40, 41] and play a con-
spicuous role in the development and progression of
RHD. Several studies showed contradictory results re-
garding the influence of HLA-G 3’UTR polymorphisms
on HLA-G expression and pathogenesis of various auto-
immune and inflammatory diseases [27–38, 42–49].
Thus it is hard to speculate the association of HLA-G
with the pathogenesis of RHD. The limitation of the
present study in ascertaining the definite role of HLA-G
in RHD could be due to the lack of soluble HLA-G quan-
tification, thereby causing difficulty to correlate the influ-
ence of 3’UTR polymorphisms on HLA-G expression.
Conclusion
In conclusion, in this pilot study we analysed for the first
time the association of HLA G 3’prime UTR polymorph-
ism in the development of RHD and the results suggest
that the +3142 C/C genotype may influence the develop-
ment of RHD and subsequent severity of the disease.
While, the 14bp Ins/Del polymorphism is not associated
with RHD risk in South Indian population. However,
further investigation by increasing the sample cohort
with diverse populations are indispensable to elucidate
the significance of HLA-G in the etiopathogenesis of
RHD.
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D' multiplied by 100. A. Healthy siblings B. RHD patients C. Trio families.
(DOC 301 kb)
Abbreviations
CI: Confidence intervals; CVL: Combined Valvular Lesions; GAS: Group A β-
hemolytic Streptococcus; HLA-G: Human Leukocyte Antigen-G; HWE: Hardy-
Weinberg equilibrium; IDC: Idiopathic dilated cardiomyopathy; JIA: Juvenile
idiopathic arthritis; LD: Linkage disequilibrium; MVL: Mitral valvular
lesions; OR: Odds ratio; RA: Rheumatoid arthritis; RF: Rheumatic fever;
RHD: Rheumatic heart disease; SLE: Systemic lupus erythematosus;
T1D: Type 1 diabetes; TDT: Transmission disequilibrium test; T-reg: Regulatory T
cells; UTR: Untranslated region
Acknowledgements
We thank the RHD patients and their family members for providing blood
samples. We are grateful to University Grants Commission, India for
providing fellowship to Mr. P. Maheshkumar under Non-NET Scheme and
UGC-CAS, UGC-NRCBS, DST-PURSE, DBT-IPLS for the instrumentation facilities.
Funding
Not applicable.
Availability of data and material
All data generated or analysed during this study are included in this
published article [and its supplementary information files].
Authors’ contributions
PM collected samples and data, performed genotyping, peformed statistical
analysis, analysed and interpreted the data, and wrote the manuscript. ES
participated in the design of the study, participated in samples and data
collection, revised the manuscript. SS participated in samples and data
collection, revised the manuscript. MJ the corresponding author, did
conception, designed and coordinated the study, analysed and interpreted
the data, revised the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by ethics committees of Government Rajaji
hospital, Madurai and Madurai Kamaraj University, Madurai.
All individuals were recruited after obtaining informed consent. For children
(<18 years), the consent was duly signed by their parents or guardians.
Author details
1Department of Immunology, School of Biological Sciences, Madurai Kamaraj
University, Madurai 625 021, Tamil Nadu, India. 2Institute of Child Health and
Research Centre, Government Rajaji Hospital, Madurai, Tamil Nadu, India.
Received: 30 September 2016 Accepted: 25 January 2017
References
1. Guilherme L, Fae K, Oshiro SE, Kalil J. Molecular pathogenesis of rheumatic
fever and rheumatic heart disease. Expert Rev Mol Med. 2005;7:1–15.
2. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune
pathogenesis of rheumatic heart disease. Autoimmunity. 2006;39:31–9.
3. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic
fever and rheumatic heart disease. Clin Epidemiol. 2011;3:67–84.
4. Kumar RK, Tandon R. Rheumatic fever & rheumatic heart disease: The last 50
years. Indian J Med Res. 2013;137:643–58.
5. Kemeny E, Grieve T, Marcus R, Sareli P, Zabriskie JB. Identification of
mononuclear cells and T cell subsets in rheumatic valvulitis. Clin Immunol
Immunopathol. 1989;52:225–37.
6. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PM,
Assis RV, et al. Human heart-infiltrating T cell clones from rheumatic
heart disease patients recognize both streptococcal and cardiac
proteins. Circulation. 1995;92:415–20.
7. Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC,
et al. T cell reactivity against streptococcal antigens in the periphery mirrors
Poomarimuthu et al. Pediatric Rheumatology  (2017) 15:10 Page 6 of 7
reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease
patients. Infect Immun. 2001;69:5345–51.
8. Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, Unlu S, et al. A shift in the
balance of regulatory T and T helper 17 cells in rheumatic heart disease.
J Investig Med. 2014;62:78–83.
9. Mukhopadhyay S, Varma S, Gade S, Yusuf J, Trehan V, Tyagi S. Regulatory T-
cell deficiency in rheumatic heart disease: a preliminary observational study.
J Heart Valve Dis. 2013;22:118–25.
10. Carosella ED, Dausset J, Rouas-Freiss N. Immunotolerant functions of HLA-G.
Cell Mol Life Sci. 1999;55:327–33.
11. Carosella ED, Rouas-Freiss N, Roux DT, Moreau P, LeMaoult J. HLA-G: An
Immune Checkpoint Molecule. Adv Immunol. 2015;127:33–144.
12. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, et al. HLA-
G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int
Immunol. 1999;11:1351–6.
13. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+)
T-Lymphocytes. J Reprod Immunol. 2000;48:17–26.
14. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLAG has a concentration-
dependent effect on the generation of an allo-CTL response. Immunology.
2000;101:191–200.
15. Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, et al. Role of
HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by
itself. J Reprod Immunol. 1999;43:175–82.
16. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P.
The 14 bp deletion-insertion polymorphism in the 3’ UT region of the HLA-
G gene influences HLA-G mRNA stability. Hum Immunol. 2003;64:1005–10.
17. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H.
Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue
Antigens. 2001;57:15–21.
18. Castelli EC, Moreau P, Oya e Chiromatzo A, Mendes-Junior CT, Veiga-Castelli LC,
Yaghi L, et al. In silico analysis of microRNAS targeting the HLA-G 3’
untranslated region alleles and haplotypes. Hum Immunol. 2009;70:1020–5.
19. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are
associated with differences in the HLA-G mRNA isoform profile and HLA-G
mRNA levels. Immunogenetics. 2003;55:63–79.
20. Larsen MH, Hviid TV. Human leukocyte antigen-G polymorphism in relation
to expression, function and disease. Hum Immunol. 2009;70:1026–34.
21. Rizzo R, Bortolotti D, Bolzani S, Fainardi E. HLA-G Molecules in Autoimmune
Diseases and Infections. Front Immunol. 2014;5:592.
22. Martin WJ, Steer AC, Smeesters PR, Keeble J, Inouye M, Carapetis J, et al.
Post-infectious group A streptococcal autoimmune syndromes and the
heart. Autoimmun Rev. 2015;14:710–25.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215.
24. Silva ID, Muniz YC, Sousa MC, Silva KR, Castelli EC, Filho JC, et al. HLA-G
3’UTR polymorphisms in high grade and invasive cervico-vaginal cancer.
Hum Immunol. 2013;74:452–8.
25. Hviid TV, Hylenius S, Hoegh AM, Kruse C, Christiansen OB. HLA-G
polymorphisms in couples with recurrent spontaneous abortions. Tissue
Antigens. 2002;60:122–32.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics. 2005;21:263–5.
27. Hachiya Y, Kawasaki A, Oka S, Kondo Y, Ito S, Matsumoto I, et al. Association
of HLA-G 3’ Untranslated Region Polymorphisms with Systemic Lupus
Erythematosus in a Japanese Population: A Case–control Association Study.
PLoS One. 2016;11:e0158065.
28. Lucena-Silva N, de Souza VS, Gomes RG, Fantinatti A, Muniz YC, de
Albuquerque RS, et al. HLA-G 3′ untranslated region polymorphisms are
associated with systemic lupus erythematosus in 2 Brazilian populations.
J Rheumatol. 2013;40:1104–13.
29. Consiglio CR, Veit TD, Monticielo OA, Mucenic T, Xavier RM, Brenol JC, et al.
Association of the HLA-G gene +3142C > G polymorphism with systemic
lupus erythematosus. Tissue Antigens. 2011;77:540–5.
30. Veit TD, de Lima CP, Cavalheiro LC, Callegari-Jacques SM, Brenol CV,
Brenol JC, et al. HLA-G +3142 polymorphism as a susceptibility marker
in two rheumatoid arthritis populations in Brazil. Tissue Antigens.
2014;83:260–6.
31. Catamo E, Addobbati C, Segat L, Sotero Fragoso T, Domingues Barbosa A,
Tavares Dantas A, et al. HLA-G gene polymorphisms associated with
susceptibility to rheumatoid arthritis disease and its severity in Brazilian
patients. Tissue Antigens. 2014;84:308–15.
32. Mariaselvam CM, Chaaben AB, Salah S, Charron D, Krishnamoorthy R,
Tamouza R, et al. Human leukocyte antigen-G polymorphism influences the
age of onset and autoantibody status in rheumatoid arthritis. Tissue
Antigens. 2015;85:182–9.
33. Silva HPV, Ururahy MAG, Souza KSC, Loureiro MB, Oliveira YMC, Oliveira
GHM, et al. The association between the HLA-G 14-bp insertion/deletion
polymorphism and type 1 diabetes. Genes Immun. 2016;17:13–8.
34. Lin A, Yan WH, Xu HH, Tang LJ, Chen XF, Zhu M, et al. 14 bp deletion
polymorphism in the HLA-G gene is a risk factor for idiopathic dilated
cardiomyopathy in a Chinese Han population. Tissue Antigens. 2007;70:427–31.
35. Veit TD, Vianna P, Scheibel I, Brenol CV, Brenol JC, Xavier RM, et al.
Association of the HLA-G 14-bp insertion/deletion polymorphism with
juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens.
2008;71:440–6.
36. Rizzo R, Hviid TV, Govoni M, Padovan M, Rubini M, Melchiorri L, et al. HLA-G
genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as
a putative susceptibility gene in systemic lupus erythematosus. Tissue
Antigens. 2008;71:520–29.
37. Veit TD, Cordero EA, Mucenic T, Monticielo OA, Brenol JC, Xavier RM, et al.
Association of the HLA-G 14 bp polymorphism with systemic lupus
erythematosus. Lupus. 2009;18(5):424–30.
38. Wu FX, Wu LJ, Luo XY, Tang Z, Yang MH, Xie CM, et al. Lack of association
between HLA-G 14-bp polymorphism and systemic lupus erythematosus in
a Han Chinese population. Lupus. 2009;18:1259–66.
39. Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC,
Massaro JD, et al. Polymorphic sites at the 3’ untranslated region of the
HLA-G gene are associated with differential hla-g soluble levels in the
Brazilian and French population. PLoS One. 2013;8:e71742.
40. Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC,
Simoes RT, et al. The genetic structure of 3’untranslated region of the HLA-
G gene: polymorphisms and haplotypes. Genes Immun. 2010;11:134–41.
41. Castelli EC, Ramalho J, Porto IO, Lima TH, Felicio LP, Sabbagh A, et al.
Insights into HLA-G genetics provided by worldwide haplotype diversity.
Front Immunol. 2014;5:476.
42. Rizzo R, Farina I, Bortolotti D, Galuppi E, Rotola A, Melchiorri L, et al. HLA-G
may predict the disease course in patients with early rheumatoid arthritis.
Hum Immunol. 2013;74:425–32.
43. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H.
Soluble HLA-G in rheumatoid arthritis. Hum Immunol. 2006;67:561–7.
44. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stignani M, et al.
HLA-G 14-bp polymorphism regulates the methotrexate response in
rheumatoid arthritis. Pharmacogenet Genomics. 2006;16:615–23.
45. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW,
Guchelaar HJ. Functional polymorphisms and methotrexate treatment
outcome in recent-onset rheumatoid arthritis. Pharmacogenomics.
2010;11:163–75.
46. Baricordi OR, Govoni M, Rizzo R, Trotta F. In rheumatoid arthritis, a
polymorphism in the HLA-G gene concurs in the clinical response to
methotrexate treatment. Ann Rheum Dis. 2007;66:1125–6.
47. Stamp LK, O’Donnell JL, Chapman PT, Barclay ML, Kennedy MA, Frampton CM,
et al. Lack of association between HLA-G 14 bp insertion/deletion
polymorphism and response to long-term therapy with methotrexate
response in rheumatoid arthritis. Ann Rheum Dis. 2009;8:154–55.
48. Lee YH, Bae SC, Song GG. Meta-analysis of associations between functional
HLA-G polymorphisms and susceptibility to systemic lupus erythematosus
and rheumatoid arthritis. Rheumatol Int. 2015;35:953–61.
49. Kim SK, Jeong KH, Kang IJ, Chung JH, Shin MK, Lee MH. Relationship
between the HLA-G 14bp insertion/deletion polymorphism and
susceptibility to autoimmune disease: a meta-analysis. Genet Mol Res.
2015;14:15839–47.
Poomarimuthu et al. Pediatric Rheumatology  (2017) 15:10 Page 7 of 7
